NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravisAarhus, ...

Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne ...

The MarketWatch News Department was not involved in the creation of this content. -- NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in ...

The resubmission follows the positive results from the HOPE-3 Phase 3 trial. ・The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of Aug. 22, 2026. ・The investigational therapy ...

The MESA data show stabilization of function in participants on sevasemten versus the predicted functional decline observed in Becker natural history ...

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater ...

Precision BioSciences Inc. (NASDAQ:DTIL) presented new preclinical findings for its PBGENE-DMD gene therapy at the Muscular ...

"As we prepare to commence the Phase1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, we're excited to present new preclinical data highlighting its potential to deliver durable, long-term functional ...

Capricor Therapeutics shares are trading higher Tuesday as the FDA resumed Deramiocel BLA review with a new PDUFA date of August 22, 2026.

Background Gut bacteria have been implicated in a wide range of health conditions, yet their potential role in preventing and treating muscle-wasting disorders remains largely unexplored. Objective We ...

Age-related hormone shifts can reduce bone mass and density, putting us at risk for osteoporosis (weak, brittle bones). Known as a “silent disease,” the condition often goes undetected until a bone ...

The MarketWatch News Department was not involved in the creation of this content. PARAMUS, N.J., March 9, 2026 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma, New Jersey, USA; President, Yukiteru Sugiyama ...